Pliant Therapeutics has undergone a fundamental transformation following the failure of its lead asset, bexotegrast, in a Phase 2b/3 trial for idiopathic pulmonary fibrosis (IPF). This event erased most of the company's value, shifting its focus to an early-stage oncology asset, PLN-101095. Interim Phase 1 data for this drug showed a promising 50% response rate in a small cohort, positioning it as the primary near-term value driver. The company maintains a strong cash position, providing a multi-year operational runway. However, the investment is now a high-risk bet on this single asset, with the upcoming late-2025 data readout serving as a critical binary catalyst. The current market valuation, trading near or below net cash, offers asymmetric upside potential but is suited only for speculative, risk-tolerant investors.